Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents

Clinical Genitourinary Cancer

Volumn 6, Issue 1, 2008, Pages 15-20

  Choueiri, Toni K ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Carbonic anhydrase IX; Hypoxia inducible factor; Sunitinib; Vascular endothelial growth factor; Von Hippel Lindau

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AXITINIB; BEVACIZUMAB; CALCIUM; HEMOGLOBIN; LACTATE DEHYDROGENASE; PHOSPHATASE; PROTEIN KINASE B; PROTEIN S6; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TENSIN; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; CALCIUM BLOOD LEVEL; CANCER CENTER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DISEASE MARKER; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TISSUE SECTION; TREATMENT OUTCOME;

EID: 43249126494     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2008.n.002     Document Type: Review

References (62)

1. A Jemal R Siegel E Ward Cancer statistics 2008 CA Cancer J Clin 58 2008 71 96
2. NK Janzen HL Kim RA Figlin Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 2003 843 852
3. WY Kim WG Kaelin Role of VHL gene mutation in human cancer J Clin Oncol 22 2004 4991 5004
4. JI Bardos M Ashcroft Hypoxia-inducible factor-1 and oncogenic signalling Bioessays 26 2004 262 269
5. D Mukhopadhyay B Knebelmann HT Cohen The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity Mol Cell Biol 17 1997 5629 5639
6. L Xu R Tong DM Cochran Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model Cancer Res 65 2005 5711 5719
7. LE Benjamin D Golijanin A Itin Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J Clin Invest 103 1999 159 165
8. RJ Motzer MD Michaelson BG Redman Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 16 24
9. RJ Motzer RA Figlin TE Hutson Sunitinib versus interferonalfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors J Clin Oncol 25 18 suppl 2007 241s (Abstract 5024).
10. B Escudier T Eisen WM Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
11. RJ Motzer TE Hutson P Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
12. JC Yang L Haworth RM Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
13. BI Rini GT Wilding G Hudes Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib J Clin Oncol 25 2007 242s (Abstract 5032).
14. B Escudier P Koralewski A Pluzanska A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma J Clin Oncol 25 18 suppl 2007 2s (Abstract 3).
15. PJ Elson RS Witte DL Trump Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma Cancer Res 48 1988 7310 7313
16. A de Forges A Rey M Klink Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis Semin Surg Oncol 4 1988 149 154
17. PA Palmer J Vinke T Philip Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2 Ann Oncol 3 1992 475 480
18. SD Fossa A Kramar JP Droz Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha Eur J Cancer 30A 1994 1310 1314
19. RJ Motzer M Mazumdar J Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
20. RJ Motzer J Bacik BA Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
21. RM Bukowski S Negrier P Elson Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group Clin Cancer Res 10 2004 6310S 6314S
22. R Suppiah PE Shaheen P Elson Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma Cancer 107 2006 1793 1800
23. TK Choueiri B Rini JA Garcia Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma Ann Oncol 18 2007 249 255
24. TM Mekhail RM Abou-Jawde G Boumerhi Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma J Clin Oncol 23 2005 832 841
25. J Atzpodien P Royston T Wandert Metastatic renal carcinoma comprehensive prognostic system Br J Cancer 88 2003 348 353
26. RM Bukowski T Eisen C Szczylik Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis J Clin Oncol 25 18 suppl 2007 240s (Abstract 5023).
27. JE Rosenberg RJ Motzer MD Michaelson Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): updated results of two phase II trials and prognostic factor analysis for survival J Clin Oncol 25 18 suppl 2007 258s (Abstract 5095).
28. CW Ryan BH Goldman PN Lara Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group J Clin Oncol 25 2007 3296 3301
29. ME Gore C Porta S Oudard Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis J Clin Oncol 25 18 suppl 2007 237s (Abstract 5010).
30. TK Choueiri JA Garcia P Elson Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy Cancer 110 2007 543 550
31. F Donskov H von der Maase Impact of immune parameters on longterm survival in metastatic renal cell carcinoma J Clin Oncol 24 2006 1997 2005
32. S George A Richmond P Elson WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients (Pts) receiving sunitinib J Clin Oncol 25 28 suppl 2007 245s (Abstract 5043).
33. MH Tan CG Rogers JT Cooper Gene expression profiling of renal cell carcinoma Clin Cancer Res 10 2004 6315S 6321S
34. N Ferrara HP Gerber J LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676
35. S Negrier D Perol C Menetrier-Caux Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6–from the Groupe Francais d'Immunotherapie J Clin Oncol 22 2004 2371 2378
36. S Negrier S Chabaud B Escudier Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC) J Clin Oncol 25 18 suppl 2007 245s (Abstract 5044).
37. SE Deprimo CL Bello J Smeraglia Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins J Transl Med 5 2007 32
38. DJ George MD Michaelson JE Rosenberg Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers J Clin Oncol 25 18 suppl 2007 243s (Abstract 5035).
39. N Zhang K Gong XY Yang Expression of hypoxia-inducible factor-1-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof [in Chinese] Zhonghua Yi Xue Za Zhi 86 2006 1526 1529
40. MS Wiesener PM Munchenhagen I Berger Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxiainducible factor-1alpha in clear cell renal carcinomas Cancer Res 61 2001 5215 5222
41. A Lidgren Y Hedberg K Grankvist The expression of hypoxiainducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma Clin Cancer Res 11 2005 1129 1135
42. MH Bui D Seligson KR Han Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clin Cancer Res 9 2003 802 811
43. Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171:2461-6.
44. AJ Pantuck Q Trinh PI Karakiewicz Use of carbonic anhydrase IX (CAIX) expression and Von Hippel Lindau (VHL) gene mutation status to predict survival in renal cell carcinoma J Clin Oncol 25 18 suppl 2007 245s (Abstract 5042).
45. M Atkins M Regan D McDermott Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer Clin Cancer Res 11 2005 3714 3721
46. T Klatte DB Seligson SB Riggs Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma Clin Cancer Res 13 2007 7388 7393
47. P Schraml K Struckmann F Hatz VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma J Pathol 196 2002 186 193
48. JH Kim CW Jung YH Cho Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma Oncol Rep 13 2005 859 864
49. H Brauch G Weirich J Brieger VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation Cancer Res 60 2000 1942 1948
50. M Yao M Yoshida T Kishida VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma J Natl Cancer Inst 94 2002 1569 1575
51. TK Choueiri SA Vaziri BI Rini Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC) J Clin Oncol 25 18 suppl 2007 238s (Abstract 5012).
52. F Okada JW Rak BS Croix Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells Proc Natl Acad Sci U S A 95 1998 3609 3614
53. LM Ellis CA Staley W Liu Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src J Biol Chem 273 1998 1052 1057
54. JB Brugarolas F Vazquez A Reddy TSC2 regulates VEGF through mTOR-dependent and -independent pathways Cancer Cell 4 2003 147 158
55. BI Rini V Weinberg S Dunlap Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma Cancer 106 2006 566 575
56. D Cho S Signoretti M Regan The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer Clin Cancer Res 13 2007 758s 763s
57. D Kedar CH Baker JJ Killion Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice Clin Cancer Res 8 2002 3592 3600
58. AH Rosendahl G Forsberg IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells Kidney Int 70 2006 1584 1590
59. S Gad V Sultan-Amar J Meric Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results Targeted Oncology 2 2007 3 6
60. MB Atkins M Hidalgo WM Stadler Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 2004 909 918
61. G Hudes M Carducci P Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
62. D Cho S Signoretti S Dabora Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma Clin Genitourin Cancer 5 2007 379 385